NCT00434967已完成3 期
A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HCT 25 mg and Placebo in Hypertensive Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 2,207
- 试验地点
- 1
- 主要终点
- Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks).
研究概览
简要总结
The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients will be eligible for enrolment into the study (Visit 1) if they fulfil all of the following criteria:
- •Provision of signed Informed Consent
- •Primary hypertension, untreated or treated with a maximum of 2 antihypertensive drugs (substances), which the patient and the physician are willing to withdraw at enrolment and replace with placebo.
- •Mean sitting DBP 90-114 mmHg (value calculated in the eCRF) at Visits 1 and 2
- •Patients will be eligible for randomisation (Visit 4) if they fulfil the following criterion:
- •Mean sitting DBP of 90-114 mmHg (value calculated in the eCRF) at the end of the 4-week single-blind placebo run-in period. The run-in period should not be shorter than 4 weeks.
排除标准
- •Pregnant or lactating women, or women of childbearing potential not practising an adequate method of contraception eg, intrauterine device, oral contraception or progesterone implant. Pregnancy must be excluded by a negative pregnancy test at Visit
- •Secondary or malignant hypertension
- •Sitting SBP of 180 mmHg or more
- •Myocardial infarction, stroke, coronary bypass surgery or transient ischaemic attack within 6 months before enrolment
- •Angina pectoris requiring more treatment than short-acting nitrates
- •Chronic use of NSAIDs
- •Aortic or mitral valve stenosis
- •Cardiac failure requiring treatment
- •Cardiac arrhythmia requiring treatment
- •Renal artery stenosis or kidney transplantation
- •Intravascular volume depletion
- •Hypersensitivity to any component of the investigational products or to any sulphonamide derived drugs
- •Concomitant disease which may interfere with the assessment of the patient
- •Past or present alcohol or drug abuse, or any condition associated with poor compliance that in the opinion of the investigator might affect the patient's participation in the study
- •Chronic liver disease
- •Concomitant or previous treatment with any other investigational drug within 20 days of enrolment
- •Previous enrolment in the present study
研究组 & 干预措施
3
Active Comparator
Hydrochlorothiazide (HCT)
干预措施: Hydrochlorothiazide (Drug)
2
Active Comparator
Candesartan cilexetil
干预措施: Candesartan cilexetil (Drug)
1
Experimental
Candesartan cilexetil + Hydrochlorothiazide Combination
干预措施: Candesartan cilexetil (Drug)
1
Experimental
Candesartan cilexetil + Hydrochlorothiazide Combination
干预措施: Hydrochlorothiazide (Drug)
1
Experimental
Candesartan cilexetil + Hydrochlorothiazide Combination
干预措施: Candesartan/HCT 32/25 mg (Drug)
结局指标
主要结局
Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks).
时间窗: 8 weeks
Change (reduction) in sitting DBP at the end of the study, when compared to sitting DBP at baseline.
Change in Sitting Systolic Blood Pressure (SBP) From Baseline to the End of the Study (Baseline to 8 Weeks)
时间窗: 8 weeks
Change (reduction) in sitting SBP at the end of the study, when compared to sitting SBP at baseline.
次要结局
- The Number of Patients With Controlled Sitting DBP and Sitting SBP in Each Treatment Group at the End of the Study(8 weeks)
- Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Hypertension Control Rate at the End of the Study (Patients With Controlled Sitting SBP and Sitting DBP).(Baseline to 8 weeks)
- To Describe Safety and Tolerability of the Study Treatments With Regard to Adverse Events Including Those That Lead to Treatment Discontinuation as Well as With Regard to Pulse Rate, Laboratory, Electrocardiographic and Physical Examination Findings.(Baseline to 8 weeks)
- To Compare Treatment With Candesartan/HCT 32/25 mg to Each of Its Components With Regard to Change From Baseline to Week 8 in Standing DBP and Standing SBP.(Baseline to 8 weeks)
- To Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Sitting DBP Control Rate at the End of the Study (Patients With Controlled Sitting DBP Are Defined as Having a Sitting DBP <90 mmHg at the End of the Study).(Baseline to 8 weeks)
- To Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Sitting DBP Responder Rate (Decrease in Sitting DBP ≥10 mmHg From Baseline to the End of the Study or a Sitting DBP <90 mmHg at the End of the Study).(Baseline to 8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mgHypertensionNCT00383929AstraZeneca1,979
Unknown
1 期
Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine BesylateHealthyNCT01845272HK inno.N Corporation40
撤回
4 期
Aliskiren Study of Safety and Efficacy in Senior HypertensivesHypertensionNCT01922141Novartis Pharmaceuticals
已完成
3 期
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention TrialHypertensionNCT00227318AstraZeneca1,000
已完成
3 期
MK0954A-264 Filter Study (0954A-264)(COMPLETED)Mild to Severe HypertensionNCT00307060Organon and Co274